Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Royalty Pharma Announces 13% Dividend Increase

GlobeNewswire January 8, 2021

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12

GlobeNewswire January 7, 2021

Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities

GlobeNewswire December 22, 2020

Royalty Pharma Announces Expansion of Leadership Team

GlobeNewswire December 21, 2020

Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals

GlobeNewswire December 7, 2020

BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management

GlobeNewswire December 7, 2020

Royalty Pharma Reports Third Quarter 2020 Results

GlobeNewswire November 10, 2020

Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation

GlobeNewswire November 2, 2020

Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders

GlobeNewswire October 20, 2020

Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020

GlobeNewswire October 19, 2020

Royalty Pharma Declares Fourth-Quarter 2020 Dividend

GlobeNewswire October 15, 2020

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders

GlobeNewswire October 13, 2020

New Ventures Funds Rebrands as Scientia Ventures

PR Newswire October 2, 2020

Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes

GlobeNewswire September 2, 2020

Royalty Pharma Declares Third-Quarter 2020 Dividend

GlobeNewswire September 2, 2020

Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes

GlobeNewswire August 25, 2020

Royalty Pharma Announces Launch of Senior Notes Offering

GlobeNewswire August 19, 2020

Royalty Pharma Reports Second Quarter 2020 Results

GlobeNewswire August 12, 2020

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

GlobeNewswire August 7, 2020

Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company's Board of Directors

GlobeNewswire August 3, 2020